Treatment of BV With First Deqularum and Then Direkt After Clindamycin

Infection, Bacterial Clinical Trial

— BV  

Official title:

Treatment of BV With First Deqularum and Then Direkt After With Vaginal Clindamycin Cream.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04067531
• Other study ID #: 12
• Status: Recruiting
• Phase: Phase 3
• Start date: August 1, 2020
• Est. completion date: December 1, 2021

Study information

• Verified date: March 2020
• Source: Skaraborg Hospital
• Contact: P-G Larsson
• Phone: +46500431000
• Email: p-g.larsson[@]vgregion.se
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Treatment of BV with first deqularum cloride and then followed with clindamycin vaginal Cream.

Description:

The hypoteses is that deqularum cloride takes away the biofilm so that clindamycin will kills the bacteria. Cure rate will be followed up after 1 month and then after 6 month

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: December 1, 2021
• Est. primary completion date: August 1, 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• healthy women with BV

Exclusion Criteria:

• women treated with antibiotics within 1 month

Related Conditions & MeSH terms

• Bacterial Infections
• Infection, Bacterial

Intervention

Drug:
• treatment of BV with first Deqularum and then direkt after with vaginal clindamycin
All patients will get the same treatment

Locations

Country	Name	City	State
Sweden	Department of Ob/Gyn, Skaraborgshospital Skövde	Skövde

Sponsors (1)

Lead Sponsor	Collaborator
Skaraborg Hospital

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	cure of BV	cure rate of BV	6 month